CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose has proven to be...
- Mechanism
- Curator reviewed
CRx-401 has a novel mechanism of action that reduces hyperglycemia while improving HDL and triglyceride levels without promoting weight gain.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Code names
- CRx-401
Which companies are running trials of CRx-401, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account